Concepedia

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

Gregory A. Wiseman, Christine A. White, Michael Stabin, William L. Dunn, William D. Erwin, Magnus Dahlbom, Andrew Raubitschek, Kastytis C. Karvelis, Timothy E. Schultheiss, Thomas E. Witzig,

European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 234 citations · 11 references

DOI

Concepts

References

11

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

David M. Goldenberg, Frank H. DeLand, Euishin Kim et al. · New England Journal of Medicine · 1978 · 758 citations

, , +17

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20<sup>+</sup>B-Cell Non-Hodgkin's Lymphoma

Thomas E. Witzig, Christine A. White, Gregory A. Wiseman et al. · Journal of Clinical Oncology · 1999 · 539 citations

, , +17

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Neil L. Berinstein, A.J. Grillo-López, Christine A. White et al. · Annals of Oncology · 1998 · 523 citations · Full text

, , +15

MIRDOSE: Personal Computer Software for Internal Dose Assessment in Nuclear Medicine

David Piwnica-Worms · 1996 · 503 citations

, , +16

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

Mark Kaminski, Kenneth Zasadny, Isaac R. Francis et al. · Journal of Clinical Oncology · 1996 · 401 citations

, , +17